Medtronic News

Medtronic Inc., the world's biggest maker of heart-rhythm devices, said fourth-quarter sales of pacemakers and defibrillators rose, surprising analysts who expected shrinking demand to continue.

The case involves cardiac resynchronization therapy devices, which deliver shocks to the heart if ventricles don't contract properly, and patents held by Mirowski Family Ventures.

Live On. Give On: Ten inspirational people will be awarded a $20,000 charitable donation and be honored at an awards celebration in Hawaii as part of the first annual Bakken Invitation MINNEAPOLIS - May 20, 2013- Medtronic, Inc.

Backed by Robust Clinical Data on Broad Product Family, New Thrombus Removal System Offers Superior Deliverability MINNEAPOLIS -- May 20, 2013 -- Expanding its portfolio of medical technology for the interventional treatment of cardiovascular disease, Medtronic, Inc.

May 14, 2013 - Medtronic, Inc. announced today it will report financial results for the fourth quarter and fiscal year 2013 on Tuesday, May 21, 2013.

May 10, 2013 - Data presented today at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions, show that Medtronic, Inc.

New Medtronic Data Show Additional Clinical Advantages in Pacing Both Ventricles Versus Conventional Right-Ventricular Pacing MINNEAPOLIS and DENVER - May 11, 2013 - Medtronic, Inc.

Medtronic : Data Show Medtronic-Exclusive LIA Software Detects Non-Medtronic Lead Issues at a Greater Rate Than Standard Impedance Monitoring Data presented today at Heart Rhythm 2013, the Heart Rhythm Society's 34^th Annual Scientific Sessions, show that Medtronic Lead Integrity Alert software detected pace/sense lead issues in non-Medtronic leads ... (more)

"Shock-Less" Late Breaking Clinical Trial: Providing Clinicians with ICD Programming Reports Improves Adherence to Evidence-Based Guidelines, Reduces All-Cause Shocks PainFree SST Trial: More Than 98 Percent of Patients with SmartShock Technology Are Free of Inappropriate Shock at One Year ADVANCE III Trial: Waiting to Deliver ICD Therapy Combined ... (more)

Cardiology device makers haven't had much good to report to investors lately. The entire medical device market has struggled with pricing pressures and other hurdles, but the headaches of heart devices -- from mature markets to Europe's financial crush -- have ramped up the pressure on industry firms such as Medtronic, Inc.

So that must mean corporate investors like Medtronic have the opportunity to swoop in and invest in promising early stage firms, correct? Well, not really says Chad Cornell, vice president of corporate development at Medtronic, who was a speaker at the annual IBF MedTech Investing Conference in Minneapolis Wednesday.

Newly designed Devices Result in Fewer Hospitalizations for Patients, Deliver Increased Longevity, and Improved Comfort MINNEAPOLIS - May 6, 2013 - Medtronic, Inc.

Medtronic Inc. won U.S. regulatory approval for its Viva device used to resynchronize the beating of the heart and reduce hospitalizations for heart failure.

's stock had its "outperform" rating restated by analysts at BMO Capital Markets in a research report issued to clients and investors on Friday, AnalystRatingsNetwork reports.

This week, Wil has some advice on what to do if your insulin pump breaks down and also how to keep insulin cool when it's very hot outside.

May 2, 2013 - In keeping with its commitment to keep physicians informed about product performance and safety, Medtronic, Inc.

Medtronic Navigation Inc. has leased 40,657 square feet of space at 1480 Arthur Ave.

A Medtronic Inc. device used to stimulate the brain to treat Parkinson's disease and other neurological conditions has a potentially life-threatening flaw that triggered the highest-level warning from U.S. regulators.

Medtronic Spine, the Memphis-based division of Medtronic Inc ., will cut about 60 local jobs as part of a strategy to reduce overall costs by 5 percent, a company spokesman confirmed.

Medtronic, Inc. announced today it has entered into an innovative partnership with the National Institute of Hospital Administration, an important think tank under China's National Health and Family Planning Commission, to carry out a series of research projects focusing on building an integrated care pathway for patients with Type 1 diabetes.